ArticleExtracellular vesicles and circulating nucleic acids2025
Inhalable exosomes to target cardiac repair.
Article in Extracellular vesicles and circulating nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Balancing stability and cellular interaction in surface-engineered small extracellular vesicles for pulmonary delivery.Materials today. Bio · 2026Article
- Broad-Spectrum Protective Effects of Lyophilized FE002-Lu Lung Fibroblast Conditioned Medium Against Acute and Chronic Pulmonary Injury in Wistar Rats.Biomedicines · 2026Article
- Article
- Mesenchymal stem cell-derived exosomes in myocardial infarction repair: therapeutic potential and scaffold-based delivery strategies.Frontiers in pharmacology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent study introduces Stem Cell-derived Exosome Nebulization Therapy (SCENT), a novel, non-invasive strategy that delivers lung spheroid cell-derived exosomes via inhalation to promote cardiac repair after myocardial infarction. This approach improves cardiac function, reduces injury, and demonstrates translational potential in both small and large animal models, offering a promising avenue for cell-free, inhalable regenerative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.